AB-Biotics reaches agreement to acquire Madrid-based Quantum Experimental
Synergies will allow these two companies to provide integral service, from discovery and patenting through to the market.
BY BIOCAT
AB-Biotics, which is traded on the Alternative Stock Market (MAB), has reached an agreement to acquire Quantum Experimental, a Madrid-based company that provides specialized services (clinical trials, contract manufacturing, regulatory services and analytics) for companies in the pharmaceutical, healthcare, cosmetic and food sectors. They have already requested a report from an independent expert, who will have to give this operation the green light before it can be approved by AB-Biotics shareholders.
Quantum Experimental currently has a portfolio of more than 150 clients. The Madrid-based company would join the R&D Outsourcing department of AB-Biotics, complementing the Catalan biotech company’s current services. “Our synergies will allow for better optimization of resources and complementary activities, so we can provide a more complete and dynamic integral service”, explained Sergi Audivert and Miquel Àngel Bonachera, co-founders and CEOs of AB-Biotics.
Pedro de la Fuente, co-founder and general manager of Quantum Experimental, and Constantino Grande, co-founder and CEO of the firm, highlighted that “the operation will allow the company to incorporate an innovative business area that will make it possible to offer integral development service throughout the healthcare market”.
For example, the combination of Quantum Experimental’s Industrial Department and AB-Biotics’ Ingredients Department will allow them to offer clients a completely integral service from the discovery phase through patenting and the regulatory process until the product is registered before going on the market. The staffs of the two companies are complementary, so the number of workers in each firm will not change.
Strategically, AB-Biotics’ current locations (headquarters in the Vallès Technology Park and the Girona Science and Technology Park) will be complemented by those of Quantum Experimental, which has its main headquarters in Madrid and additional offices in Mexico and Brazil. This will help AB-Biotics introduce their products, such as the Neurofarmagen genetic test, in these markets.